These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34957642)

  • 21. Tumor segmentation analysis at different post-contrast time points: A possible source of variability of quantitative DCE-MRI parameters in locally advanced breast cancer.
    Romeo V; Cavaliere C; Imbriaco M; Verde F; Petretta M; Franzese M; Stanzione A; Cuocolo R; Aiello M; Basso L; Amitrano M; Lauria R; Accurso A; Brunetti A; Salvatore M
    Eur J Radiol; 2020 May; 126():108907. PubMed ID: 32145597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signal-to-noise ratio, contrast-to-noise ratio and pharmacokinetic modeling considerations in dynamic contrast-enhanced magnetic resonance imaging.
    Li X; Huang W; Rooney WD
    Magn Reson Imaging; 2012 Nov; 30(9):1313-22. PubMed ID: 22795931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast MRI during lactation: effects on tumor conspicuity using dynamic contrast-enhanced (DCE) in comparison with diffusion tensor imaging (DTI) parametric maps.
    Nissan N; Allweis T; Menes T; Brodsky A; Paluch-Shimon S; Haas I; Golan O; Miller Y; Barlev H; Carmon E; Brodsky M; Anaby D; Lawson P; Halshtok-Neiman O; Shalmon A; Gotlieb M; Faermann R; Konen E; Sklair-Levy M
    Eur Radiol; 2020 Feb; 30(2):767-777. PubMed ID: 31529255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone Parameter: Comparison With Dynamic Contrast-Enhanced and Multiparametric Magnetic Resonance Imaging.
    Pinker K; Moy L; Sutton EJ; Mann RM; Weber M; Thakur SB; Jochelson MS; Bago-Horvath Z; Morris EA; Baltzer PA; Helbich TH
    Invest Radiol; 2018 Oct; 53(10):587-595. PubMed ID: 29620604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.
    Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O
    Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The kinetic analysis of breast cancer: An investigation of the optimal temporal resolution for dynamic contrast-enhanced MR imaging.
    Matsukuma M; Furukawa M; Yamamoto S; Nakamura K; Tanabe M; Okada M; Iida E; Ito K
    Clin Imaging; 2020 May; 61():4-10. PubMed ID: 31945688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A feasible high spatiotemporal resolution breast DCE-MRI protocol for clinical settings.
    Tudorica LA; Oh KY; Roy N; Kettler MD; Chen Y; Hemmingson SL; Afzal A; Grinstead JW; Laub G; Li X; Huang W
    Magn Reson Imaging; 2012 Nov; 30(9):1257-67. PubMed ID: 22770687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision.
    Bertani V; Urbani M; La Grassa M; Balestreri L; Berger N; Frauenfelder T; Boss A; Marcon M
    Eur Radiol; 2020 Jul; 30(7):4069-4081. PubMed ID: 32144463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy and precision of quantitative DCE-MRI parameters: How should one estimate contrast concentration?
    Wake N; Chandarana H; Rusinek H; Fujimoto K; Moy L; Sodickson DK; Kim SG
    Magn Reson Imaging; 2018 Oct; 52():16-23. PubMed ID: 29777820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A deep matrix factorization framework for identifying underlying tissue-specific patterns of DCE-MRI: applications for molecular subtype classification in breast cancer.
    Fan M; Yuan W; Liu W; Gao X; Xu M; Wang S; Li L
    Phys Med Biol; 2021 Dec; 66(24):. PubMed ID: 34787109
    [No Abstract]   [Full Text] [Related]  

  • 32. Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer.
    Barnes SL; Sorace AG; Loveless ME; Whisenant JG; Yankeelov TE
    NMR Biomed; 2015 Oct; 28(10):1345-56. PubMed ID: 26332194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DCE-MRI texture analysis with tumor subregion partitioning for predicting Ki-67 status of estrogen receptor-positive breast cancers.
    Fan M; Cheng H; Zhang P; Gao X; Zhang J; Shao G; Li L
    J Magn Reson Imaging; 2018 Jul; 48(1):237-247. PubMed ID: 29219225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Joint Prediction of Breast Cancer Histological Grade and Ki-67 Expression Level Based on DCE-MRI and DWI Radiomics.
    Fan M; Yuan W; Zhao W; Xu M; Wang S; Gao X; Li L
    IEEE J Biomed Health Inform; 2020 Jun; 24(6):1632-1642. PubMed ID: 31794406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging.
    Consolino L; Longo DL; Dastrù W; Cutrin JC; Dettori D; Lanzardo S; Oliviero S; Cavallo F; Aime S
    Int J Cancer; 2016 Jul; 139(2):404-13. PubMed ID: 26941084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of enhancement kinetics in dynamic contrast-enhanced MRI and implication of distant metastasis in invasive breast cancer.
    Zhao R; Ma WJ; Tang J; Chen YZ; Zhang LN; Lu H; Liu PF
    Clin Radiol; 2020 Dec; 75(12):961.e25-961.e32. PubMed ID: 32859381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer.
    Dogan BE; Yuan Q; Bassett R; Guvenc I; Jackson EF; Cristofanilli M; Whitman GJ
    Curr Probl Diagn Radiol; 2019; 48(3):235-240. PubMed ID: 29685400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer.
    Onishi N; Sadinski M; Hughes MC; Ko ES; Gibbs P; Gallagher KM; Fung MM; Hunt TJ; Martinez DF; Shukla-Dave A; Morris EA; Sutton EJ
    Breast Cancer Res; 2020 May; 22(1):58. PubMed ID: 32466799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diagnostic performance of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in evaluating the pathological response of breast cancer to neoadjuvant chemotherapy: A meta-analysis.
    Li Z; Li J; Lu X; Qu M; Tian J; Lei J
    Eur J Radiol; 2021 Oct; 143():109931. PubMed ID: 34492627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinically feasible method to estimate pharmacokinetic parameters in breast cancer.
    Li J; Yu Y; Zhang Y; Bao S; Wu C; Wang X; Li J; Zhang X; Hu J
    Med Phys; 2009 Aug; 36(8):3786-94. PubMed ID: 19746812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.